To describe the response to nemolizumab in a patient with severe, treatment-refractory brachioradial pruritus (BRP).
Approach:
Patient: A 65-year-old woman had more than 4 years of bilateral arm pruritus, burning, and pain, with a positive ice-pack sign and impaired sleep.
Prior treatment: Symptoms persisted despite topical therapies, gabapentin, pregabalin, and naltrexone; pregabalin and naltrexone were continued when nemolizumab was started.
Nemolizumab and assessment: Treatment began with a 60 mg loading dose followed by 30 mg every 4 weeks. Itch was assessed using the worst itch numerical rating scale (WI-NRS), and quality of life using DLQI and ItchyQoL.
Key Findings:
Within 10 days, WI-NRS decreased from 7–9/10 to 3/10 and subsequently was most often 0–1/10.
The itch reduction persisted during the 3-month observation period.
DLQI and ItchyQoL scores declined markedly after the first dose, indicating improved quality of life.
Interpretation:
The authors report a rapid, sustained antipruritic response and quality-of-life improvement in this patient, while noting that the evidence for biologic therapy in BRP remains limited.
Limitations:
This was a single case with concomitant antipruritic treatment.
Observation was brief, and clinical photographs were unavailable before and during treatment.
The biopsy was performed externally, and histological slides were unavailable for review.
Cervical spine imaging was not performed; diabetes and glycemic-control fluctuations may have contributed to pruritus.
Conclusion:
The authors state that nemolizumab may be an option for selected patients with severe, refractory BRP, but additional studies are needed to validate the observation.